Clostridium difficile infection is a risk factor for bacteremia due to vancomycin-resistant enterococci (VRE) in VRE-colonized patients with acute leukemia.

Department of Medicine, University of Maryland School of Medicine and Veterans Affairs Maryland Health Care System, Baltimore 21201, USA.
Clinical Infectious Diseases (Impact Factor: 9.37). 12/1997; 25(5):1056-9. DOI:10.1086/516112
Source: PubMed

ABSTRACT A cohort study was conducted in a cancer center to identify risk factors for bacteremia with vancomycin-resistant enterococci (VRE) in neutropenic cancer patients colonized with VRE. There were 10 patients with VRE bacteremia among 56 colonized with VRE, of whose charts 51 were available for review. One hundred percent of patients with VRE bacteremia (10 of 10) vs. 56% of patients without VRE bacteremia (23 of 41) had acute leukemia (P = .01, Fisher's exact test). Four of the 10 patients with VRE bacteremia had a positive Clostridium difficile toxin assay within 6 days of their first positive VRE blood culture. Both C. difficile infection and antimicrobial (vancomycin and ciprofloxacin) use during VRE colonization were significant risk factors for VRE bacteremia in univariate analysis. When a Cox proportional hazards model was used to account for differences in follow-up time, C. difficile infection was the only statistically significant risk factor (risk ratio, 8.2; P = .007) for VRE bacteremia in VRE-colonized patients with acute leukemia.

0 0
  • [show abstract] [hide abstract]
    ABSTRACT: The incidence and severity of Clostridium difficile-associated disease(CDAD) within the general population has risen dramatically over the past decade , yet little data is available from hematopoetic stem transplantation centers(HSCT). In the present study, we performed a chart review of 822 consecutive autologous and allogeneic HCST recipients treated at NMH between 2004-2008 to determine the incidence of CDAD at our institution. Variables including age, sex, diagnosis, chemotherapy regimen, transplant type, microbial colonization, co-infections, diet, antibiotics use, neutropenic fever, co-morbid conditions, time to engraftment, growth factors administration, and occurrence of graft versus host disease were assessed as potential risk factors for the development of CDAD. Eighty five CDAD cases (10.3%) were identified. Bivariate analysis revealed a significant association between CDAD and neutropenic fever , administration of a neutropenic diet, ciprofloxacin aztreonam duration of therapy , vancomycin and aztreonam use and duration of therapy , receipt of an allogeneic transplantation , bacterial co-infection, and VRE colonization. Cox regression analysis identified age >60, allogeneic transplantation and prior VRE colonization as factors associated with the development of CDAD. Allogeneic recipients with CDAD experienced increased higher rates of grade II-IV GI GVH and non-relapse mortality. A risk stratification model was developed to identify HSCT recipients at different levels of risk. With an incidence >10%, CDAD is a significant infectious complication of stem cell transplantation.
    Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation 12/2012; · 3.15 Impact Factor
  • [show abstract] [hide abstract]
    ABSTRACT: The prevalence and severity of Clostridium difficile infection (CDI) has increased over time in adult patients, but little is known about CDI in pediatric cancer. The primary objectives were to describe the incidence and characteristics of CDI in children with de novo acute myeloid leukemia (AML). The secondary objective was to describe factors associated with CDI. We performed a multicenter, retrospective cohort study of children with de novo AML and evaluated CDI. Recurrence, sepsis and infection-related death were examined. Factors associated with CDI were also evaluated. Forty-three CDI occurred in 37 of 341 (10.9%) patients during 42 of 1277 (3.3%) courses of chemotherapy. There were 6 children with multiple episodes of CDI. Three infections were associated with sepsis, and no children died of CDI. Only 2 children had an associated enterocolitis. Both days of broad-spectrum antibiotics (odds ratio 1.03, 95% confidence interval: 1.01 to 1.06; P = 0.003) and at least 1 microbiologically documented sterile site infection (odds ratio 10.81, 95% confidence interval: 5.88 to 19.89; P < 0.0001) were independently associated with CDI. CDI occurred in 11% of children receiving intensive chemotherapy for AML, and outcomes were not severe. CDI is not a prominent issue in pediatric AML in terms of prevalence, incidence or associated outcomes.
    The Pediatric Infectious Disease Journal 06/2013; 32(6):610-613. · 3.57 Impact Factor
  • [show abstract] [hide abstract]
    ABSTRACT: Many infections of immunocompromised patients originate from the gastrointestinal tract. The pathogenesis of these infections often begins with alteration of the intestinal microbiota. Understanding the microbiota and how it can either cause or prevent infection is vital for the development of more effective prevention and treatment of these infections. This article reviews and discusses recent work providing insight into the intestinal microbiota of these at-risk immunocompromised patients. Studies continue to support the premise that commensal bacteria, largely anaerobic, serve to maintain microbial stability and colonization resistance by preventing overgrowth or domination with more pathogenic bacteria, through interactions within the microbial community and with the host. In patients with immune suppression due to high-dose chemotherapy or hematopoietic stem cell transplantation, disruption of the microbiota through antibiotics as well as impairment of host immunity gives rise to perturbations favoring intestinal domination by pathogenic species, leading to increased bacterial translocation and susceptibility to systemic infection. An understanding of the intestinal microbiota and the impact of antibiotics will help to guide our treatment of these gut-originating infections.
    Current Opinion in Infectious Diseases 08/2013; 26(4):332-337. · 4.87 Impact Factor


1 Download
Available from

M C Roghmann